Eli Lilly 2005 Annual Report Download - page 85

Download and view the complete annual report

Please find page 85 of the 2005 Eli Lilly annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 100

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100

PROX Y S TATEM ENT
8383
Performance Graph
This graph compares the return on Lilly stock with that of Standard & Poor’s 500 Stock Index and our peer group*
for the years 2001 through 2005. The graph assumes that, on December 31, 2000, a person invested $100 each in
Lilly stock, the S&P 500 Stock Index, and the peer group’s common stock. The graph measures total shareholder
return, which takes into account both stock price and dividends. It assumes that dividends paid by a company are
reinvested in that company’s stock.
Comparison of Five-Year Cumulative Total Return Among Lilly, S&P 500 Stock Index, and Peer Group*
VALUE OF $100 INVESTED ON LAST BUSINESS DAY OF 2000
Dec. 2000 Dec. 2001 Dec. 2002 Dec. 2003 Dec. 2004 Dec. 2005
$120
$110
$100
$90
$80
$70
$60
2000 2001 2002 2003 2004 2005
Lilly $100.00 $85.62 $70.62 $79.89 $65.93 $ 67.60
S&P 500 $100.00 $88.17 $68.73 $88.41 $98.00 $102.80
Peer Group $100.00 $86.53 $67.37 $74.04 $71.27 $ 69.71
* We constructed the peer group as the industry index for this graph. It comprises the eight companies in the
pharmaceutical industry that we used to benchmark 2005 compensation of executive officers: Abbott Laboratories;
Bristol-Myers Squibb Company; GlaxoSmithKline; Johnson & Johnson; Merck & Co.; Pfizer, Inc. (including the
results of Pharmacia Corporation up to the time of its merger with Pfizer); Schering-Plough Corporation; and
Wyeth (formerly American Home Products Corporation).